Please ensure Javascript is enabled for purposes of website accessibility

These 3 Things Make a Healthcare Stock Evergreen

By Alex Carchidi – May 15, 2021 at 6:25AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It isn't easy to stand the test of time.

There isn't much that the best healthcare stocks have in common with firs and pines -- except, of course, being evergreen. 

When the seasons change in the market, evergreen healthcare stocks stay as healthy and vibrant as always. While there's no expectation that these stocks will grow like weeds, they're far more hardy, and that makes them excellent investments to anchor your portfolio. Let's take a look at three competitive factors that I've found to be shared by the most consistent and formidable healthcare stocks.

Two mature people smile at one another sitting at a table in front of a laptop and stack of papers.

Image source: Getty Images

1. Targeting markets that will never disappear

Some healthcare companies make a name for themselves by developing solutions to emergent problems -- like a vaccine or therapeutics to combat the coronavirus pandemic, for instance. As necessary as this type of work might be, the market for coronavirus products isn't going to always be as rapidly growing or as dynamic as it is right now. In fact, the more successful the vaccine manufacturers are at getting their jabs into arms, the faster the market's growth will taper.

In the long run, that's a problem for companies that are still in the process of getting their products through the clinical trials process. By the time their medicines get approved for sale, their addressable market will be smaller than when they started the projects, and it'll also be crowded with competitors. 

In contrast, the most enduring healthcare stocks tend to target markets that are relatively timeless. As an example, Abbott Laboratories (ABT 2.85%) makes a plethora of different surgical tools like stents and catheters, all of which are going to be in demand for as long as people need surgeries. It also makes a bunch of different diagnostics that doctors will need to figure out what's going on with patients, which is a permanent feature of their jobs (to say the least).

Having such stable business as a fact of life means that Abbott can afford to pay its dividend each quarter and increase its dividend each year for the last 49 years in a row

2. Having a strong competitive moat

Competitive moats are factors that make it harder for a company's competitors to take their market share. So, having more moats and stronger moats results in competitive advantages that drive a stock's growth and viability in the long term. For healthcare companies, moats can be anything from a unique product to intellectual property (IP) protections to high switching costs for customers to defect to a competitor. 

Consider Intuitive Surgical (ISRG 3.16%), maker of the da Vinci robotic surgical suite. Intuitive has several different moats, the first of which is that surgeons need to be trained to use the da Vinci system specifically. This means that if hospitals want to switch from Intuitive's product to use another surgical suite, the surgeons will need to be retrained. In other words, there's a substantial time cost associated with switching to a competitor, which makes Intuitive's business more defensible.

Furthermore, Intuitive's robots are covered by intellectual property protection and trade secrets, and its brand is perhaps the most powerful in its market. In sum, its business is well-protected, and it doesn't have any threatening competitors of a similar size.

ABT Total Return Level Chart

ABT Total Return Level data by YCharts

3. Constantly reinvesting in the future of the company

Investors love companies that perform stock buybacks and pay out dividends. But the best healthcare businesses prioritize investing in the company's ability to make more money tomorrow than it makes today. In the long run, reinvestment of earnings makes it easier to reward shareholders too. 

Consider Abbott Labs. In 2020, it paid out $2.56 billion in dividends, and spent $173 million on share repurchases. It also spent $2.42 billion on research and development (R&D) in addition to repaying $1.3 billion in long-term debt. Despite spending a significant sum on rewarding its shareholders, Abbott spent even more on investing in future growth opportunities and supporting its future cash flows.

With R&D spending like that, it's no surprise that the company can develop so many new products. More importantly, its commitment to the future is one thing that it has in common with other evergreen healthcare stocks.

Alex Carchidi owns shares of Abbott Laboratories. The Motley Fool owns shares of and recommends Intuitive Surgical. The Motley Fool recommends the following options: long January 2022 $580 calls on Intuitive Surgical and short January 2022 $600 calls on Intuitive Surgical. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT
$99.52 (2.85%) $2.76
Intuitive Surgical, Inc. Stock Quote
Intuitive Surgical, Inc.
ISRG
$193.36 (3.16%) $5.92

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
326%
 
S&P 500 Returns
102%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/04/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.